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rterial hypertension a prominent component of a number of 
endocrine disorders, most prominently those involving the adrenal 
glands (pheochromocytoma, primary aldosteronism and Cushing 
syndrome) and the pituitary (ACTH-producing tumors). Hypertension may 
also be a prominent feature of other endocrine disorders such as 
acromegaly, thyrotoxicosis, hypothyroidism, and hyperparathyroidism.  
Endocrine hypertension is noted in both adults and children but it is more relevant for children 
where it comes second to renal hypertension, the common cause of hypertension in that age group.  
 
Hypertension of Adrenal Origin 
The adrenal hormones with greatest effect on 
blood pressure (BP) are mineralocorticoids. 
The major adrenal secretory products with 
mineralocorticoid activity are aldosterone and 
11-deoxycorticostereone (DOC). Cortisol also 
has high intrinsic mineralocorticoid activity 
but, its actions in the kidney are blunted by 
local degradation. Aldosterone is produced 
exclusively in the zona glomeurlosa of the 
adrenal gland and is primarily controlled by 
the renin–angiotensin system. Other 
regulators include sodium (Na+) and 
potassium (K+) plasma concentrations, 
pituitary ACTH, and dopamine. With the 
exception of 18-hydroxycorticosterone, the 
precursors of aldosterone that originate in the 
zona glomerulosa are normally present in 
very low concentrations in the peripheral 
blood. In the zona fasciculata, the two major 
biosynthetic pathways are under the control of 
ACTH. The major product formed by the 17–
hydroxy pathway is cortisol. The principal 
steroid product of the 17-deoxy pathway with 
significant mineralocorticoid activity is DOC. 
Corticosterone and 18-
hydroxydeoxycorticosterone are also 
produced in substantial amounts, but these 
steroids have relatively little 
mineralocorticoid activity in humans. 
Aldosterone, in contrast to steroids made in 
the zona fasciculata, binds weakly to 
Professor of Child Health, Endocrine & Metabolic 
Diseases 
University of Khartoum -Sudan 
  
corticosteroid- binding globulin (CBG), and 
circulates mostly bound to albumin. Free 
aldosterone comprises 30-50% of its total 
plasma concentration, whereas the free 
fractions of the steroid products of the zona 
fasciculata comprise 5-10% of their total 
concentration. Consequently, aldosterone has 
a relatively short half–life on the order of 15-
20 minutes. Aldosterone is rapidly inactivated 
in the liver, with formation of 
tetrahydroaldosterone. Another metabolite, 
aldosterone-18-glucuronide is formed by the 
kidney and usually represents 5-10% of the 
secreted aldosterone, but it has no 
mineralocorticoid activity. A small amount of 
free aldosterone appears in the urine and can 
be easily quantitated. Aldosterone secretion 
rates vary from 50 to 250 µg/day on sodium 
intake in the range of 100-150 mmol/day. 
DOC is secreted at approximately the same 
rate as aldosterone. However, like cortisol. 
DOC is almost totally bound to CBG, with 
less than 5% appearing in the free form. It is 
metabolized in the liver to 
tetrahydrodeoxycorticosterone, conjugated 
with glucuronic acid, and excreted in the 
urine. There is virtually no free DOC 
detectable in the urine. The mineralocorticoid 
activity reflects the availability of free 
hormone and the affinity of the hormone for 
the receptor. Aldosterone and DOC have 
approximately equal and high affinities for 
the mineralocorticoid receptor and circulate at 
roughly similar concentrations, but 
aldosterone is quantitatively the most  
A 
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important because much more of it is in the 
free form. Cortisol has an affinity for the 
receptor similar to that of aldosterone and its 
free levels in the circulation are about 100 
folds higher than those of aldosterone. 
Because of this, cortisol is the major steroid 
that occupies the mineralocorticoid receptors 
in many tissues such as the pituitary and the 
heart; however, at normal circulating levels, 
cortisol does not contribute much to 
mineralocorticoid action in typical target 
tissues (kidney, colon, and salivary glands) 
because of local conversion via 11β–
hydroxysteroid dehydrogenase to cortisone. 
Cortisol can lead to mineralocorticoid 
hypertension when this conversion is blunted 
by deficiency or inhibition of this enzyme. 
Aldosterone and other minerlocorticoids 
influence certain ion–transporting epithelia 
with high Na+-K+ ATPase levels. The 
principal effects of the mineralocorticoids are 
on maintenance of normal Na+ and K+ 
concentrations and extracellular fluid volume. 
Mineralocorticoids cross the cell membrane 
and combine with a mineralocorticoid 
receptor in the cytosol. The active steroid 
receptor complex moves into the nucleus of 
the target cell where it alters the rate of 
transcription of mineralocorticoid–responsive 
genes with subsequent change in the levels of 
specific mRNAs and their protein product. 
The aldosterone–induced proteins include 
factors that regulate the luminal Na+ channel, 
facilitating movement of Na+ into cells, and 
components of the Na+-K+ ATPase pump. 
The principal early effect of aldosterone, 
beginning in less than 1 hour, is on the Na+ 
channel. Without altering overall channel 
abundance, aldosterone increases the apical 
membrane targeting in the collecting tubules 
and part of the distal convoluted tubules. 
Recently a key mediator of this early response 
was identified as an aldosterone-regulated 
kinase that increases Na + channel activity. 
The later effects, 6-24 hours after 
administration of aldosterone, include 
activation of Na+-K+ ATPase and alterations 
in cell morphology and energy metabolism. 
Some or all of these effects may be due to the 
altered intracellular Na+ concentration, which 
result from the primary effect on the Na+ 
channel. In addition to directly enhancing Na+ 
absorption, the major effect of these changes 
in ion transport is to increase the difference in 
electrical potential across the renal tubule. 
The increased luminal negativity augments 
tubular secretion of K+ by the principal cell 
and hydrogen ions (H+) by the intercalated 
cell. Tubular Na+ enters the extracellular fluid 
via the Na+ pump and helps maintain its 
normal composition and volume. All of these 
events occur in other secretory systems as 
well and can be measured in saliva, sweat, 




Mineralocorticoid hormones produce 
hypertension by several mechanisms. The 
initiating events are the physiologic 
consequences of mineralocorticoid-induced 
expansion of plasma and extracellular fluid 
volume. The understanding of these 
mechanisms comes form studies in normal 
subjects given high doses of 
mineralocorticoids and form sequential 
observations made following discontinuation 
of spironolactone therapy in patients with 
aldosterone-secreting adenomas. Initially, Na+ 
and fluid retention occur, with an increase in 
body weight, extracellular fluid volume, and 
cardiac output. After gaining 1-2 liters of 
additional extracellular fluid, the phenomenon 
of Na+ “escape” follows so that a new steady 
state is achieved. Renal K+ wasting persists 
and arterial blood pressure continues to 
increase. Typically, the chronic stage of 
mineralocorticoid excess is characterized by 
an increase in total peripheral vascular 
resistance and normalization of stroke volume 
and cardiac output. The increase in peripheral 
vascular resistance is related in part to 
increased sensitivity to catecholamines even 
without a distinct increment in plasma 
adrenaline or noradrenaline levels. An 
additional mechanism may be a direct central 
action of aldosterone. Infusion of aldosterone 
in the ventricles of the brains of rats produced 
hypertension that could not be reversed or 
prevented by infusion, at the same site, of a 
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competitive aldosterone antagonist. Primary 
mineralocorticoid excess is manifested by 
hypertension, hypokalemia, and suppression 
of the renin-angiotensin system. Clinically 
similar syndromes can result from increased 
adrenal production of other steroids with 
mineralocorticoid activity like DOC, failure 
to inactivate cortisol (the syndrome of 
apparent mineralocorticoid excess), or as a 
consequence of  mineralocorticoid-
independent augmentation of renal Na+ 
reabsorption due to a constitutively activated 
epithelial Na+ channel (e.g. Liddle’s 
syndrome ). The presence of these latter 
disorders is often suggested by clinical 
findings of mineralocorticoid excess in a 
patient with subnormal aldosterone levels.  
 
Primary Hyperaldosteronism:  
Increase production of aldosterone by 
abnormal zona glomerulosa tissue (adenoma 
or hyperplasia) initiates the series of events 
that result in the typical clinical 
manifestations of the syndrome of primary 
hyperaldosteronism. A benign aldosterone-
producing adenoma, as originally described 
by Conn, accounts for 75% of cases of 
primary hyperaldosteronism. Idiopathic 
hyperaldosteronism, a disorder with many 
similar clinical features, accounts for most of 
the remaining cases. In idiopathic 
hyperaldosteronism the adrenals are either 
normal in appearance or, more commonly, 
reveal bilateral micro or macronodular 
adrenal hyperplasia. Increased renal Na+ 
retention results in expansion of the 
extracellular fluid volume and increased total 
body Na+ content. Although the effects on the 
kidney are greatest quantitatively, other 
mineralocorticoid target tissues are also 
affected. Fecal excretion of Na+, for example, 
can be decreased to almost nil, with a 
measurable effect on the rectal potential 
difference. Salivary electrolyte ratios can also 
reflect the influence of hyperaldosteronism on 
that target tissue. The expanded extracellular 
fluid and plasma volumes are sensed by 
stretch receptors at the juxtaglomerular 
apparatus and Na+ flux at the macula densa, 
with resultant suppression of renin secretion, 
measured as suppressed plasma renin activity. 
Suppression of the renin-angiotensin system, 
while not of it self diagnostic of primary 
aldosteronism, is thus a major feature of this 
disorder. In addition to Na+ retention 
potassium depletion develops, decreasing the 
total body and plasma concentration of K+. 
The extrusion of potassium from its 
intracellular reservoir is followed by the 
intracellular movement of H+ and, together 
with aldosterone-dependent increase in renal 
secretion of H+, results in metabolic alkalosis. 
With moderate potassium depletion, 
decreased carbohydrate tolerance and 
increased resistance to vasopressin occur 
leading to polyuria. Severe K+ depletion 
blunts baroreceptor function, occasionally 
producing postural hypotension. Primary 
hyperaldosteronism is a disease of the zona 
glomerulosa. Other adrenal product formed in 
this zone such as DOC, corticosterone, and 
18-hydroxycorticosterne may be present in 
increased amounts in the blood or urine of 
persons with an aldosterone producing 
adenoma. Cells of this zone do not have the 
ability to make cortisol. Thus, there are no 
abnormalities in either cortisol production or 
metabolism. Plasma and urine cortisol levels 
are normal. 
Clinical Features: Patients typically come to 
medical attention because of symptoms of 
hypokalemia or detection of previously 
unsuspected hypertension during the course of 
a routine physical examination. The medical 
history reveals no characteristic symptoms 
other than non specific complaints of fatigue, 
loss of stamina, weakness, and lassitude, all 
of which are symptoms of K+ depletion. If K+ 
depletion is more severe, thirst, polyuria, 
headache and paresthesias may also be 
present. Excessive production of 
mineralocorticoids produces no characteristic 
physical findings. Blood pressure in patients 
with primary hyperaldosteronism can range 
from borderline elevation to severe 
hypertension, but accelerated or malignant 
hypertension is extremely rare. Orthostatic 
decreases in blood pressure without reflex 
tachycardia are observed in the severely K+ 
depleted patient because of blunting of the 
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baroreceptors signals. A positive Trousseau or 
Chvostek sign is suggestive of alkalosis and 
hypocalcemia that accompany severe 
potassium depletion. The heart is usually only 
mildly enlarged and electrocardiographic 
changes reflecting modest left ventricular 
hypertrophy and potassium depletion may be 
detected.  Frank heart failure and clinical 
edema are uncommon. 
Diagnosis: Detection of spontaneous 
hypokalemia is often the initial clue that 
suggests a diagnosis of primary 
hyperaldosteronism in a patient with 
hypertension. During the investigation, a high 
potassium diet or potassium supplements 
should be avoided, and all previous diuretic 
therapy must be discontinued for at least three 
weeks before a valid serum or plasma 
potassium measurement can be obtained. The 
most common cause of hypokalemia in 
patients with hypertension is diuretic therapy. 
In some series, up to 20% of patients with 
primary hyperaldosteronism have had normal 
serum potassium concentrations. Serum 
potassium concentration is closely related to 
and determined to a great extent by sodium 
intake. A low Na+ diet, by reducing delivery 
of Na+ to aldosterone-sensitive sites in the 
distal nephron, can reduce renal K+ secretion 
and thus correct hypokalemia. On the other 
hand, increased distal delivery of Na+ 
accompanying a high Na+ diet can enhance K+ 
loss, particularly when aldosterone is being 
secreted autonomously and is therefore not 
subject to the normal suppression by the high 
Na+ intake. These physiologic relationships 
serve to illustrate the importance of 
controlling the dietary Na+ intake when 
evaluating patients suspected of having 
primary hyperaldosteronism. In the presence 
of normal renal function and autonomous 
aldosterone production, salt loading will 
usually unmask hypokalemia. In most of the 
western countries, the average person 
consumes more than 120 mmol of Na+ per 
day, enough to allow hypokalemia to become 
manifest when present. If a dietary history of 
high salt intake is obtained and the K+ 
concentration is normal, a diagnosis of 
primary hyperaldosteronism is unlikely. 
Patients who report a low Na+ intake should 
be advised to take an unrestricted diet plus 1 g 
of sodium chloride with each meal for four 
days and blood samples for electrolyte 
determinations should be obtained in the 
fasting state on the following morning. This 
dietary regimen is also useful because it 
prepares the patient for optimal measurement 
of renin and aldosterone levels. Assessment of 
the renin-angiotensin system can be 
accomplished by a random plasma rennin 
activity measurement. If plasma rennin 
activity is normal or high in a patient who has 
not been receiving diuretic therapy for at least 
three weeks, it is very unlikely that an 
aldosterone-producing adenoma is present. 
However, some patients with idiopathic 
hyperaldosteronism may have low normal 
levels of plasma rennin activity. On the other 
hand, a subnormal plasma renin level is not 
alone sufficient to establish a diagnosis of 
primary hyperaldosteronism, since a large 
subgroup of patients with essential 
hypertension have low plasma renin levels. If 
hypokalemia and suppressed renin activity are 
detected, plasma and urinary aldosterone 
measurements should be obtained while the 
patient is taking an unrestricted salt diet. This 
is crucial, because with any significant 
diminution of slat intake, plasma aldosterone 
concentration and aldosterone production 
normally increase. Assessment of aldosterone 
production can best be accomplished by 
measurement of urinary excretion of 
aldosterone or one of its metabolite over a 24 
hour period. Most laboratories measure 
excretion of the 18-glucuronide metabolite. 
The normal rate of urinary excretion of this 
metabolite ranges from 5-20 µg/day. Urinary 
measurements are superior to random 
measurements of plasma aldosterone for the 
detection of abnormal production of 
aldosterone but are not always able to 
discriminate between patients with adenoma 
and those with idiopathic hyperaldosteronism. 
Samples for measurements of plasma 
aldosterone concentration should ideally be 
obtained at around 8:00 AM after at least 4 
hours of recumbency and under the same 
dietary conditions as described above for 
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measurement of urinary aldosterone. This 
measurement not only confirms the presence 
of hyperaldosteronism but also provides 
insight into the probable underlying 
pathology. When obtained under these 
conditions, a plasma aldosterone 
concentration greater than 25 ng/dl 
(695pmol/l) usually indicates the presence of 
an aldosterone-producing adenoma. The 
plasma aldosterone level should also be 
determined after 2-4 hours in the upright 
posture, which normally activates the rennin 
system with a resultant increase in the plasma 
aldosterone level. Ninety Percent of patients 
with adenoma will show no significant 
change or an obvious decrease in plasma 
aldosterone levels, whereas aldosterone levels 
almost always increase in those with 
idiopathic hyperaldosteronism. The difference 
is due to: (1) The profound suppression of the 
renin system by excessive aldosterone 
production in patients with an adenoma (2) 
the influence of ACTH, to which the adenoma 
is still responsive and which normally 
decreases between 8 AM and 12 noon; and 
(3) decreased responsiveness of adenomas to 
angiotensin-II. In contract in patient with 
idiopathic hyperaldosteronism, increased 
sensitivity of the gland to small increase in 
renin and angiotensin-II levels that occur in 
the upright posture leads to an increased 
aldosterone secretion. Serum cortisol levels 
must be measured simultaneously. An 
increase in serum cortisol implies an ACTH 
discharge and invalidates the information 
obtained from the maneuver. Some 
investigators have advocated the use of the 
aldosterone/renin ratio as a means of 
screening for and perhaps establishing a 
diagnosis of primary hyperaldosteronism. A 
ratio in excess of 30 (assuming that 
aldosterone levels are reported in nanograms 
per deciliter and renin levels in nanograms per 
milliliter per hour) is considered abnormal. 
However, since a low renin level (e.g. 0.1 
ng/ml/h) can result in an elevated ration even 




range (e.g. 3 ng/dl), use of the ratio in the  
absence of a concomitantly elevated 
aldosterone level should be discouraged. 
Measurement of other adrenal steroids may 
add to the precision of diagnosis. Plasma 
DOC, corticosterone, and particularly, 18–
hydroxycorticosterne levels are frequently 
increased in patients with primary 
hyperaldosteronism, whereas they are rarely if 
ever increased in patients with idiopathic 
hyperaldosteronism. Increased urinary 
excretion of 18-hydroxycrotisol and 18-
oxocortisol, which is a characteristic finding 
in individuals with the dexamethasone–
suppressible form of primary 
hyperaldosteronism, may also be present in 
some patients with aldosterone-producing 
adenomas. The procedures just discussed can 
confirm a diagnosis of primary 
hyperaldosteronism and differentiate adenoma 
from idiopathic hyperaldosteronism in most 
patients. Localization studies can also provide 
additional information. When uncertainty 
persists, the saline infusion test may be useful. 
Saline loading establishes aldosterone 
unresponsiveness to volume expansion and 
thereby identifies autonomy in patients with 
aldosterone-producing adenomas. Two litres 
of isotonic saline are administered over 24 
hours. Blood samples for aldosterone and 
cortisol measurements are obtained before 
and after the infusion. Expansion of the 
extracellular fluid volume reduces plasma, 
aldosterone concentration promptly in 
patients with idiopathic hypertension but fails 
to suppress plasma aldosterone concentration 
into the normal range in patients with 
adenoma or hyperplasia. Moreover, the saline 
infusion test typically distinguishes patients 
with primary hyperaldosteronism from those 
with low-renin essential hypertension. The 
ratio of aldosterone to cortisol is typically 
greater than 3.0 following administration of 
saline in patients with an aldosterone-
producing adenoma reflecting the limited 
effect of volume expansion in the setting of 
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Rare Form of Primary Hyperaldo stero- 
nism  
A:Dexamethasone-Remediable Aldostero- 
nism: This is a rare form of genetic 
hypertension that has been recognized with 
increasing frequency since the molecular 
basis of this disorder was established. It is 
inherited in an autosomal dominant pattern. 
The primary defect is a gene duplication that 
results from an unequal crossing over event 
that fuses the regulatory region of the 11β-
hydroxylase gene to the coding sequence of 
aldosterone synthase. With cortisol as a 
substrate, expression of this enzyme in the 
zone fasciculata results in the synthesis of 18–
hydroxycortisol and 18-oxocortisol 
(phenotypic markers of this disorder). 
Aldosterone secretion also occurs in this zone 
and is ACTH-dependent, such that small 
doses of dexamethasone (1-2 mg/day) can 
ameliorate hypertension as well as the typical 
biochemical findings. However, the response 
to dexamethasone suppression may diminish 
with prolonged use in many patients, and 
additional antihypertensive therapy may thus 
be necessary. The presence of 
dexamethasone-remediable hypertension 
should be considered in any family with 
primary hyperaldosteronism. The diagnosis 
can easily be established by measurement of 
the marker steroids (18-oxocortisol &18-
hydroxycortisol) or by detection of the 
abnormal gene in the DNA samples. 
B:Aldosterone-producing Adrenal 
carcinoma:  
Malignant adrenal tumors producing 
aldosterone in the absence of hypercortisolism 
is rare, accounting for less than 3% of cases 
of primary hyperaldosteronism. In general, 
the biochemical and hormonal features and 
the response to dynamic tests are similar to 
those in patients with adenoma except that the 
size of the anomalies is greater. 
Hypercortisolism, hyperandrogenism and 
hyperestrogenism may also be found. 
 
Management of Aldosterone-producing 
Adenomas:  
Once the biochemical diagnosis is secure, 
localization of the site of the adenoma helps 
with surgical management. A number of 
techniques are in use including: CT and MR 
imaging, adrenal isotope scanning and adrenal 
vein catheterization. The diagnostic 
information provided by CT and MRI in 
locating adenomas has proved to be both 
accurate and practical and thus it is the initial 
procedure of choice. Scanning using 
radioisotopes can identify the tumor in 80% 
of patients, but success rate decreases 
markedly if the tumor is less than 1 cm, in 
diameter. Obtaining blood samples from 
adrenal veins on both sides for measurement 
and comparison of aldosterone level continues 
to be useful in lateralizing tumors after other 
techniques fail. Cortisol levels should be 
measured simultaneously to confirm the 
source of the sample and extent of mixing 
with non-adrenal blood. Injection of dye in 
the adrenal vein (venography) is hazardous 
and is no longer utilized. Treatment depends 
on accurate diagnosis. When the diagnosis 
and lateralization is certain, surgical removal 
of the adenoma or unilateral adrenalectomy 
via a laparoscope is recommended. Ideally, 
patients should be treated preoperatively with 
spironolactone until the BP and serum K+ are 
normal. This drug is particularly beneficial 
because it blocks the mineralocorticoid 
receptor and inhibits aldosterone synthesis by 
adenomas. It normalizes the extracellular fluid 
volume, promotes K+ retention and activates 
the suppressed renin-angiotensin system, 
which in turn promotes normal secretion of 
aldosterone by the healthy gland. 
Postoperative hypoaldosteronism and 
hyperkalemia is unlikely with this kind of 
action. Spironolactone is well tolerated 
usually; the side effects of rashes, 
gynecomastia, impotence and epigastric 
discomfort are rare and disappear with 
continuation of medication. In patients who 
fail to tolerate the drug, the K+-sparing 
diuretic amiloride can be used as an 
alternative. Other antihypertensive drugs may 
also be required to obtain optimal control of 
BP. Calcium channel blockers are particularly 
effective in this setting. The postoperative 
cure rate of hypertension is recorded in over 
70% of patients in most studies, with partial 
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reduction of hypertension in the remainder. 
Subtotal adrenalectomy will correct 
hypokalemia in patients with idiopathic 
hyperaldosteronism but hypertension is rarely 
cured. Therefore, antihypertensive medication 
is needed and such patients should not be 
routinely sent to surgery. A subset of patients 
with primary hyperaldosteronism but no 
identifiable adenoma, referred to as primary 
adrenal hyperplasia, also benefit from surgical 
reduction of adrenal mass. If surgery is 
contraindicated or refused by the patient, 
prolonged treatment with spironolactone can 
be effective. The initial dose of 200-400 
mg/day must be continued for 4-6 weeks 
before the full effect on BP is realized, but a 
maintenance dose of 75-100 mg/day is 





DOC is the second most important naturally 
occurring mineralocorticoid hormone. 
Accordingly, excess DOC should be 
suspected in any hypertensive patient with 
hypokalemia and suppression of renin and 
aldosterone production. 
 
CONGENITAL ADRENAL HYPER- 
PLASIA 
11β-hydroxylase Deficiency: Congenital 
adrenal hyperplasia due to 11β -hydroxylase 
deficiency is usually recognized in newborns 
and infants because of virilization and the 
presence of hypertension and hypokalemia. 
Plasma androgens, 11-deoxycortisol, 17α-
hydroxyprogesterone, urinary 17-ketosteroids, 
and 17-hydroxycorticosteroid are increased. 
The defect has been identified in the gene, 
which is mapped on chromosome 8. It is 
usually partial, so that some cortisol is 
produced but it does not increase with further 
ACTH stimulation. Blood levels of cortisol 
are usually within normal limits. A partial 
defect of 11β-hydroxylation results in 
increased production and high blood levels of 
DOC, 11-deoxycortisol, and androgens. 
Hypertension results from excessive 
production of DOC by mechanisms similar to 
those described for aldosterone over secretion 
earlier. The blood levels and production rates 
of aldosterone are normal or reduced in this 
condition. Two mechanisms are proposed. 
Originally, a partial deficiency of the 11β-
hydroxylation activity in the zona 
glomerulosa was postulated, with a block in 
aldosterone synthesis. This concept was 
supported by the observation that after 
normalization of DOC production and 
correction of the hypertension by ACTH 
suppression, aldosterone production remained 
normal or reduced and a Na+-losing state 
could be provoked. Currently, it is felt that 
there is no defect in the zona glomerulosa but 
that suppression of renin by the increased 
production of DOC reduces the production of 
aldosterone. Thus, after chronic salt 
restriction and ACTH suppression, both renin 
and aldosterone dynamics return to normal, 
implying an intact zona glomerulosa. 
17α-Hydroxylase Deficiency: The deficiency 
of this key enzyme in the steroid biosynthesis 
cycle prevents production of androgens and 
estrogens, and decreases production of 
cortisol. The defect occurs in a single gene on 
chromosome 10, which codes for the enzyme. 
The diminution in cortisol production induces 
surge in ACTH production. As a result all non 
17-hydroxylated steroids products are 
increased including DOC and aldosterone. 
The subsequent expansion of extracellular 
fluid and blood volume leads to hypertension 
and suppression of the renin-angiotensin 
system, which in turn causes suppression of 
aldosterone production. Thus the principal 
steroids present in excess are: DOC, 
corticosterone, 18-hydroxycortisol and 18-
hydroxydeoxycorticosterone. There has been 
no instance in which the adrenal defect occurs 
without the gonadal defect and the condition 
is usually recognized at the time of puberty by 
presence of hypertension, hypokalemia and 
primary amenorrhea in the female or 
feminized genitalia in the male. Patients often 
have eunuchoid proportions and younger age 
appearance. The virtual absence of 17α-
hydroxyprogestrone, pregnanetriol, and 17 
keto-steroids is diagnostic.   
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Treatment of 17α and 11β-Hydroxylase 
Deficiency: Treatment of both of these 
disorders is similar to that of all non-Na+-
losing forms of congenital adrenal 
hyperplasia. Treatment with physiologic 
replacement doses of glucocorticoid, such as 
hydrocortisone or dexamethasone, restores 
blood pressure to normal levels, corrects K+ 
depletion, reduces excessive DOC and 
corticosterone production in 17 α-hydroxylase 
deficiency, and reduces DOC and 11-
deoxycortisol production in 11 β-hydroxylase 
deficiency. In 17 α-hydroxylase deficiency 
syndrome, restoration of normal levels of 
DOC results in a return of plasma renin 
activity and aldosterone to normal values. A 
delay in return of the suppressed renin-
aldosterone system toward normal can result 
in hypovolemic crises with initial natriuresis 
and diuresis. It may take several years before 
the aldosterone, and renin systems become 
normal. The amount of glucocorticoid 
administered must be carefully determined 
because of apparently exquisite tissue 
sensitivity to glucocorticoid hormones. 
Addition of estrogen-progesterone combined 
cyclic therapy may be necessary in the adult 
patient with 17 α-hydroxylase deficiency.  
 
Androgen & Estrogen-Producing Adrenal 
Tumors: Most of the C-19 steroids produced 
by the adrenocortical zona reticularis have 
weak androgen activity, especially 
dehydroepiandrosterone (DHEA) and it is 
sulfate (DHEAS) as well as androstenedione. 
Disturbance in both internal zona reticularis 
regulatory mechanisms (enzyme activity) and 
its extra-adrenal regulators (ACTH and an 
androgen-stimulating peptide of possible 
hypothalamic-pituitary origin) may lead to 
excessive adrenal sex steroid production, 
resulting in syndromes of hirsutism and 
virilization in females or feminization in 
males. Although the zona reticularis has no 
intrinsic capacity to synthesize any effective 
glucocorticoid or mineralocorticoid, it has the 
potential, under conditions of chronic 
stimulation by ACTH, to transform some 
cellular function into the fasciculata cell type 
and produce cortisol and presumably other 
typical zona fasciculata steroids. Some 
patients with malignancies originating in the 
zona reticularis may have clinical features of 
mineralocorticoid excess, with hypertension, 
hypokalemia, and renin suppression. 
Aldosterone levels are generally not elevated 
and are often reduced. Urinary or plasma 
steroid profiling in some of these patients 
suggests that there may be inhibition of 11β- 
hydroxylase activity in association with the 
increased production of androgens or 
estrogens. Administration of 
methylandrostanediol to experimental animals 
and testosterone to humans suggests that 
exogenous androgen excess can block the 
conversion of 11-deoxycortisol and DOC to 
cortisol and corticosterone, respectively. 
Excessive secretion of DOC could then lead 
to a state of mineralocorticoid excess. 
Increased urinary excretion of DOC 
metabolites or plasma DOC concentrations 
have been found in several patients with 
androgen or estrogen-producing 
adrenocortical carcinomas who have 
hypertension and hypokalemia. The inhibition 
of 11β-hydroxylase in these patients may be 
due to inactivation of the enzyme cytochrome 
CYP11B1 by the high intra-adrenal 
concentration of androgens that act as a 
pseudosubstrate for the reaction. This 
mechanism is similar to that occurring in 
Cushing's syndrome, in which cortisol 
appears to serve as the enzymatic inhibitor.  
 
Syndrome of Primary Cortisol Resistance: 
Peripheral resistance to cortisol action is a 
very rare condition in which severe 
hypertension, hypokalemia, and renin 
suppression are associated with elevated 
plasma and urinary levels of cortisol without 
causing clinical manifestations of Cushing's 
syndrome. The basic defect is at the level of 
the glucocorticoid receptor; both the number 
of receptors and the affinity of the receptors 
for cortisol are reduced in the target tissues. In 
this condition, plasma levels of ACTH are 
elevated as a result of block of cortisol 
feedback at the corticotroph. Cortisol 
production is thus increased, but it does not 
result in the typical clinical stigmas of 
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hypercortisolism. However, chronic 
stimulation by excess ACTH of the 17-deoxy 
pathway of the zona fasciculata results in 
abnormal production of DOC and 
corticosterone, causing hypertension, 
hypokalemia, and suppression of renin and 
aldosterone production. The clinical and 
biochemical abnormalities are partially 




Hypertension is a common finding of 
endogenous hypercortisolism but occurs in 
only 10-20% of patients receiving therapy 
with synthetic glucocorticoids. ACTH-
dependent hypercortisolism (Cushing's 
disease and ectopic ACTH production) is 
frequently accompanied by increased levels of 
other ACTH-dependent steroids, especially 
DOC and corticosterone. The elevated DOC 
and cortisol levels probably contribute to the 
mineralocorticoid excess state. Plasma renin 
activity varies but is typically normal as a 
consequence of concomitant increase in the 
production of angiotensinogen. Serum K+ 
levels are also normal in most patients, 
implying the absence of a mineralocorticoid 
excess state. However, a small subset of 
patients has hypokalemia and suppressed 
plasma renin levels. Most of these patients 
have ectopic ACTH hypersecretion or adrenal 
tumors. Even when there is evidence for 
mineralocorticoid excess, suppressed plasma 
renin and hypokalemia, levels of aldosterone 
and 18-hydroxycorticosterone are consistently 
within or below the normal range. 
Hypertension in Cushing's syndrome is 
usually more frequent in patients with 
adrenocortical hyperplasia, due to ACTH 
excess, than in patients with cortical 
adenomas, which implies that, in addition to 
cortisol, other ACTH-dependent steroids 
(DOC, corticosterone & 18-
hydroxydeoxycorticosterone) may contribute 
to the development or maintenance of 
hypertension. In addition, urinary excretion of 
the potent naturally occurring 
mineralocorticoid 19-nor-DOC, produced in 
the kidney by the conversion of an 
oxygenated form of DOC, is elevated in both 
the primary (adrenal) and secondary 
(pituitary) forms of Cushing's syndrome. 
Since most patients with Cushing’s syndrome 
do not have findings consistent with 
hyperminealocorticoidism, glucocorticoids 
appear to cause hypertension by 
mineralocorticoid-independent mechanisms. 
These include increased production of 
angiotensin-II due to glucocorticoid-induced 
increases in the hepatic synthesis of 
angiotensinogen; enhanced glucocorticoid-
mediated vascular reactivity to 
vasoconstrictors; inhibition of extra neuronal 
uptake and degradation of catecholamines; 
inhibition of vasodilatory systems such as 
kinins and prostaglandins; shift in Na+ from 
the intracellular to the extracellular 
compartment, resulting in increased plasma 
volume; and an increase in cardiac output 
from the increased production of  adrenaline 
due to enhanced phenylethanolamine-N-




The term pseudohyperaldosteronism 
comprises heterogeneous group of disorders 
in which the clinical features are consistent 
with mineralocorticoid excess yet endogenous 
mineralocorticoid secretion is abnormally low 
due to suppressed renin production. Renin 
secretion is suppressed by increased Na+ 
retention and volume expansion, resulting 
either from the presence of endogenous or 
exogenous mineralocorticoids or 
mineralocorticoid-like substances or from a 
mineralocorticoid-independent increase in 
renal tubular sodium transport. Hypertension, 
hypokalemia, and metabolic alkalosis are the 
usual manifestations. In addition to the 
syndrome that result from excess production 
of DOC as described above, continuous use of 
fluorinated steroids with powerful 
mineralocorticoid-like activity contained in 
some topical preparation such as nasal sprays 
and dermatologic creams can be associated 
with hypertension, hypokalemia and renin and 
aldosterone suppression. Withdrawal of these 
medications or adjustment of the dosage 
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easily controls undesirable side effects. 
Pseudohyperaldosteronism can also occur as a 
prominent feature of several rare syndromes, 
the pathophysiologic features of which have 
only recently been established.  
 
Syndrome of Apparent Mineralocorticoid 
Excess: A rare disorder, initially designated 
as the syndrome of apparent 
mineralocorticoid excess, is characterized by 
findings suggestive of a 
hypermineralocorticoid state: hypertension, 
hypokalemia, suppressed renin levels, and 
amelioration by spironolactone, despite low 
levels of aldosterone and DOC. Most of the 
reported cases have been in children who 
have severe hypertension. Although the 
pathogenesis remained elusive for more than 
a decade, it is now evident that the primary 
abnormality in this disorder is reduced 
peripheral metabolism of cortisol due to a 
mutation in the gene encoding 11β-
hydroxysteroid dehydrogenase type 2, the 
isoenzyme that is present in greatest 
abundance in the renal tubule. Impaired 
conversion of cortisol to cortisone in the cells 
of the renal tubule results in an accumulation 
of cortisol and subsequent occupancy of 
mineralocorticoid receptors. Despite normal 
plasma cortisol levels, urinary cortisol is 
increased, reflecting impairment of the 
kidney's ability to convert cortisol to 
cortisone. The increased urinary excretion of 
tetrahydrocortisol (THF) and reduced 
excretion of tetrahydrocortisone (THE) leads 
to a marked increase in the THF/THE ratio, a 
finding considered diagnostic of this disorder. 
Treatment consists of the administration of 
small doses of dexamethasone (0.75-1 mg/d) 
to suppress ACTH and to limit thereby the 
production of cortisol and its accumulation in 
mineralocorticoid target tissues in the kidney. 
  
Chronic Ingestion of Licorice: Chronic 
ingestion of large amounts of substances 
containing mineralocorticoid-like activity, 
e.g. certain candies, infusions, drinks and 
some chewing tobaccos containing licorice, 
results in a syndrome of hypertension, 
hypokalemia, renal Na+ retention, volume 
expansion, suppressed plasma renin activity, 
and metabolic alkalosis. The secretion and 
excretion of aldosterone and its precursors are 
low or undetectable. The responsible agent for 
this syndrome is the active principle of 
licorice, glycyrrhizic acid, and its metabolite 
glycyrrhetinic acid, that are present in certain 
commercially available products. Both of 
these alkaloids inhibit 11 β -hydroxysteroid 
dehydrogenase in the kidney, which increases 
free cortisol locally to act as the 
mineralocorticoid in a manner similar to the 
syndrome of apparent mineralocorticoid 
excess. Pseudohyperaldosteronism can be 
induced by licorice and its derivative 
carbenoxolone, which is used in treatment of 
gastric ulcers. Electrolyte abnormalities and 
hypertension disappear within a few weeks 
upon discontinuation of licorice ingestion or 
withdrawal of carbenoxolone treatment. 
 
Liddle’s Syndrome: In 1963, Liddle and his 
colleagues reported the results of studies in a 
large family in which the affected members 
had clinical manifestations resembling those 
of primary hyperaldosteronism. Aldosterone 
production, however, was negligible. The 
inheritance pattern in this family was that of 
an autosomal dominant disorder, and the 
phenotype was soon identified in several 
additional families as well as in sporadic 
cases. Although these findings suggest the 
possibility of excessive production of another 
mineralocorticoid, none has been 
documented. In contrast to patients with 
excess DOC production or those with the 
syndrome of apparent mineralocorticoid 
excess, administration of the 
mineralocorticoid antagonist spironolactone 
to patients with Liddle’s syndrome did not 
correct neither the hypertension, nor the 
hypokalemia. Furthermore, the glucocorticoid 
synthesis blocking agent metyrapone, which 
inhibits 11 β and 18-hydroxylation of 
aldosterone precursors, also had no effect. 
Interestingly, administration of triamterene, a 
diuretic agent with K+ sparing activity 
independent of mineralocorticoid antagonism, 
was effective in controlling the hypertension 
and the hypokalemia. The investigators 
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proposed that a primary defect in the renal 
tubule, which enhances Na+ reabsorption, was 
responsible. Recent studies on many families 
and patients with this syndrome have 
supported the suggested hypothesis. Using 
linkage studies as well as electrophysiologic 
techniques, it has been established that 
patients with Liddle’s syndrome have a defect 
in the cytoplasmic domain of either the β or γ 
subunit of the epithelial Na+ channel that 
result in constitutive activation of the channel. 
Since triamterene as well as amiloride are 
relatively specific inhibitors of this channel, 
treatment with these agents will correct the 
hypokalemia and ameliorate the hypertension. 
  
Type II Pseudohypoaldosteronism: The 
term type II pseudohypoaldosteronism, also 
known as Arnold-Healy-Gordon Syndrome, 
has been used to describe a rare clinical 
syndrome in which hypertension is present in 
association of hyperkalemia, impairment of 
renal K+ excretion, hyperchloremic metabolic 
acidosis and hyporeninemic 
hypoaldosteronism. The GFR is usually 
normal and the mineralocorticoid resistance is 
shown by persistence of hyperkalemia and 
subnormal kaliuretic response to large doses 
of exogenously administered 
mineralocorticoid hormone. However, in 
contrast to patients with classic form of 
mineralocorticoid resistance (type 1 
pseudohypoaldosteronism), salt wasting is not 
present and both the anti-natriuretic and anti-
chloruretic responses to mineralocorticoid are 
intact. Impaired renal K+ secretion was 
initially proposed as the primary defect. 
However, whereas fractional renal K+ 
excretion was subnormal and increased only 
minimally when Na+ was delivered to the 
distal nephron segments as NaCl, distal renal 
K+ secretion increased greatly when Na+  was 
delivered distally in the presence of non-Cl--
anions (sulfate and bicarbonate). These 
findings indicate that the renal K+ secretory 
mechanism is intact and suggested an 
alternative hypothesis in which the primary 
defect was proposed to increase the 
reabsorptive avidity of the distal nephron for 
Cl-. This, in turn, would (1) limit the Na+ and 
mineralocorticoid-dependent driving force for 
K+ and H+ secretion, resulting in hyperkalemia 
and acidosis; and (2) augment distal NaCl 
reabsorb ion, resulting in hyperchloremia, 
volume expansion, and hypertension. 
Consistent with the presence of such a 
“chloride shunt” restriction of dietary NaCl or 
administration of a chloruretic diuretic 
(furosemide, thiazides) ameliorates 
hyperkalemia and acidosis in such patients. 
  
OTHER HORMONE SYSTEMS & 
HYPERTENSION 
INSULIN: Hyperinsulinemia and insulin 
resistance have been implicated as potential 
factors in the generation of hypertension, 
particularly in obese patients. It has been 
argued that insulin resistance is present in 
most obese patients with hypertension and in 
some non-obese hypertensive patients. In the 
setting of obesity there is impaired insulin-
mediated glucose uptake resulting in both 
type 2 diabetes mellitus and increased insulin 
secretion by the pancreas (hyperinsulinemia). 
The distribution of body fat may also be a key 
factor, in as much as hypertension and insulin 
resistance are seen more commonly in 
patients with abdominal obesity. The 
association of hypertension, diabetes mellitus, 
abdominal obesity, and hyperlipidemia has 
been referred to as “syndrome X” or the 
syndrome of insulin resistance. The 
hypertension observed in this clinical 
syndrome may be due in part to the 
hyperinsulinemia. Insulin accentuates the 
activity of the sympathetic nervous system, 
leading to greater vasoconstriction. In 
addition, insulin increases renal Na+  
reabsorption, resulting in increased 
intravascular volume and blood pressure. 
Although insulin usually induces 
vasodilatation to counter-balance these 
pressor forces, in the setting of obesity this 
action is attenuated. Thus, in these insulin-
resistant states, it is postulated that the 
stimulation of both the sympathetic nervous 
system and renal Na+ reabsorption by 
hyperinsulinemia combined with impaired 
vasodilatation results in increased blood 
pressure. It is noteworthy that weight loss 
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lowers blood pressure, insulin levels, and 
insulin resistance in these patients.  Increase 
insulin levels alone are probably not sufficient 
to cause hypertension given the observations 
that experimental animals receiving high 
doses of insulin and patients with insulinomas 
do not develop hypertension. In addition, 
there are a substantial number of patients with 
obesity, insulin resistance, and type 2 diabetes 
mellitus who do not have hypertension (e.g. 
Pima Indians in the US). Thus, there is 
probably a critical interplay of genetic and 
hormonal factors in the pathogenesis of 
hypertension in patients with insulin 
resistance. 
 
NATRIURETIC PEPTIDES: Extracts of 
aterial but not ventricular tissue cause marked 
natriuresis when injected into rats. The 
material is contained in densely staining 
granules in the atria of most mammalian 
species. Atrial natriuretic peptide (ANP) is a 
28-amino-acid peptide derived from the 
cleavage of the carboxyl terminal of a 126-
amino-acid precursor located primarily in the 
storage vesicles of atrial cells. At least three 
other natriuretic peptides have subsequently 
been identified; a brain natriuretic peptide 
(BNP) C-type peptide (CNP), and a renal 
natriuretic peptide (urodilatin). Although 
originally described in the brain, the major 
source of BNP is the cardiac ventricle, and its 
action is similar to that of ANP. CNP is 
mainly produced in the brain, where it serves 
as a neurotransmitter and in endothelial cells, 
where it may regulate vasoconstriction. 
Urodilatin is produced in the kidney, where it 
acts locally to affect Na+ transport. These 
natriuretic peptides bind to membrane 
receptors linked to guanylyl cyclase, resulting 
in production of the second messenger, 
cGMP. The major effects seen following the 
administration of ANP are vasodilatation, 
hyperfiltration, and natriuresis. Although the 
peptide can cause relaxation of vascular 
smooth muscle the fall in blood pressure is 
thought to be due largely to reduction of 
venous return and depression of cardiac 
output in intact animals. In the kidney, ANP 
increases GFR probably by inducing a 
relative afferent arteriolar dilation and 
efferent arteriolar vasoconstriction and an 
increase in glomerular permeability. The 
natriuresis is due both to the increase in GFR 
and to the direct inhibition by ANP of Na+ and 
water reabsorption by inner medullar and 
cortical collecting duct cells. ANP inhibits 
secretion of renin, aldosterone, vasopressin 
and ACTH as well as the stimulation of heart 
rate mediated by the baroreceptors. 
Maneuvers that expand plasma volume and 
increase arterial pressure are associated with 
increased levels of ANP in plasma. Thus, 
when blood volume increases stretch may 
trigger secretion of the peptide and lead to 
natriuresis and blood pressure reduction. 
However, the precise role ANP plays in the 
control of Na+ balance, blood volume and 
blood pressure regulation under normal 
physiologic conditions is not clear, and there 
are no known roles for impaired ANP 
secretion in the pathogenesis or maintenance 
of essential hypertension. Because of the 
pharmacologic effects of the natriuretic 
peptide to induce vasodilatation, 
hyperfiltration and natriuresis, studies are 
under way to determine if these peptides may 
have a therapeutic role in the treatment of 
hypertension, heart failure, and renal failure. 
Whether ANP will be a useful therapy for 
congestive heart failure is uncertain because 
most of the patients with chronically elevated 
arterial blood pressures already have 
increased plasma levels of the peptide.  
 
ENDOTHELIUM-DERIVED RELAXING 
FACTOR: The vascular endothelium 
produces a labile substance, endothelium-
derived relaxing factor (EDRF) that mediates 
the vasorelaxant actions of various 
endogenous hormones including 
acetylcholine. EDRF has been identified as 
nitric oxide, which is synthesized form the 
guanidine nitrogen atom of the amino-acid L-
arginine by the enzyme nitric oxide synthase. 
Nitric oxide diffuses within the cell or to 
adjacent cells such as smooth muscle cells, 
where it stimulates soluble guanylyl cyclase. 
The resultant increase in cyclic guanosine 
monophosphate leads to relaxation of the 
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vascular smooth muscles and therefore 
vasodilatation. A number of recent studies in 
laboratory animals and human subjects have 
shown that nitric oxide synthesized by the 
vascular endothelium is an important 
determinant of resting peripheral vascular 
resistance and blood pressure. In anesthetized 
rabbits, inhibition of the nitric oxide synthase 
activity using substituted arginine analogs 
acutely increased blood pressure. This 
hypertensive effect can be reversed by the 
infusion of arginine. In normal subjects, 
infusion of L-arginine decreases peripheral 
vascular resistance, causing hypotension and 
reflex tachycardia. Because of his apparently 
important role of nitric oxide in maintaining 
basal blood pressure it has been proposed that 
the nitric oxide pathway may be abnormal in 
patients with hypertension. This view has 
been supported by recent studies in humans. 
For example, patients with essential 
hypertension have a diminished 
vasoconstrictor response to an infusion of 
arginine analogs and a reduced arterial 
vasodilator response to acetylcholine, 
suggesting that both the basal and stimulated 
release of nitric oxide is reduced in this 
disease. In contrast, the response to the 
endothelium-independent vasodilator 
nitroprusside was normal in patients with 
essential hypertension, suggesting that the 
abnormality is a result of reduced nitric oxide 
production by the endothelium rather than 
impaired response in the vascular smooth 
muscle. The   mechanisms responsible for this 
endothelial dysfunction are not known 
 
ENDOTHELIN:  
In addition to the production of the potent 
vasodilator nitric oxide, the vascular 
endothelium produces a potent 
vasoconstrictor peptide which is called 
endothelin. At least three endothelin peptides 
have been identified: endothelin-1, 
endothelin-2, and endothelin-3. The 
predominant vascular vasoconstrictor 
endothelin-1 is formed form proendothelin-1 
by the action of a metalloprotease, endothelin-
converting enzyme. Endothelin-1 binds to 
receptors in vascular smooth muscle, which 
are linked to phospholipids C, resulting in the 
hydrolysis of phosphoinositide to inositol 
triphosphate. Increased endothelin activity has 
been observed in disorders associated with 
vasoconstriction such as malignant 
hypertension, heart failure, pulmonary 
hypertension, contrast-induced acute tubular 
necrosis, and myocardial infarction. A rare 
tumor, hemangioendothelioma, can cause 
hypertension by the secretion of large 
quantities of endothelin. In addition, the 
hypertension associated with the use of 
cyclosporine may be due to increased 
endothelin production. However, a conclusive 
role of endothelin in the pathogenesis of 
essential hypertension has not been 
demonstrated. 
 
KALLIKREIN-KININ SYSTEM: Kinins 
are potent vasodilators formed in blood 
vessels. They are cleaved from the precursor 
kininogen by the enzymatic action of 
kallikrein. Kallikrein activity has been noted 
to be reduced in patients with essential 
hypertension, suggesting lower vasodilator 
kinin production. ACE is known to inactivate 
bradykinin, leading to the suggestion that the 
hypertensive effect of ACE inhibitors may be 
due, in part, to increased bradykinin levels. 
Moreover, the improved insulin sensitivity 
and glucose utilization observed in diabetic 
patients treated with ACE inhibitors may be 
the result of increased kinin levels rather than 
reduced angiotensin II production. 
 
OTHER HORMNES & AUTACOIDS: 
Prostaglandins, vasopressin, calcitonin gene-
related peptide, parathyroid hormone, and 
parathyroid hormone-related peptide are 
vasoactive hormones or autacoids that have 
been implicated in the regulation of blood 
pressure. Although vasopressin is both a 
potent vasoconstrictor and prime factor in 
water reabsorption by the kidney, it does not 
appear to be a factor in the pathogenesis of 
essential hypertension. Calcitonin gene-
related peptide is a potent vasodilator 
produced in the central nervous system and in 
autonomic nerves innervating blood vessels. 
It has been suggested that calcitonin gene- 
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related peptide may mediate the hypotensive 
effect of calcium supplements shown in 
hypertensive patients. Both infusions of 
parathyroid hormone and parathyroid 
hormone-related peptide can produce 
hypotension. Thus, the hypertension 
commonly seen in primary 
hyperparathyroidism is probably due to other 
factors. 
 
SYMPATHETIC NERVOUS SYSTEM: 
Increased activity of the nervous system has 
been implicated as a contributing factor in the 
pathogenesis of essential hypertension. This 
may be due to both genetic and environmental 
factors. Some patients with hypertension, 
particularly during the early stages, as well as 
normotensive offsprings of hypertensive 
patients have enhanced sympathetic nervous 
system activity. It has been postulated that 
impaired baroreceptor function may prevent 
the normal inhibitory check on increase in 
sympathetic activity. In addition, the role of 
stress in the generation and maintenance of 
hypertension is probably mediated, in part, by 
activation of the sympathetic nervous system. 
The mechanisms by which increased 
sympathetic nervous system activity and 
catecholamines increase blood pressure is 
multi-factorial, including augmented 
vasoconstriction, increased cardiac output, 
increased activity of the renin-angiotensin 
system , and enhanced Na+  reabsorption by 
the kidney.  
 
PHEOCHROMOCYTOMA 
Pheochromocytomas are tumors arising from 
the chromaffin cells of the sympathetic 
nervous system in the adrenal medulla. They 
release adrenaline or noradrenaline or both 
and in some cases dopamine into the 
circulation, causing hypertension and other 
signs and symptoms. In addition to 
catecholamines, pheochromocytomas produce 
a wide variety of active peptides. These 
include: vasopressin, somatostatin, substance 
P, corticotrophin-releasing hormone, 
adrenocorticotropin, endorphin, lipotropin,  
 
 
vasoactive intestinal polypeptide, interleukin- 
6, parathyroid hormone-related protein, 
neuropeptide-Y, gastrin, metenkephalin, 
serotonin, calcitonin, calcitonin-related 
peptide, neurotensin, pancreastatin, galanin 
and insulin-like growth factor II. These 
tumors are found in both sexes at all ages, but 
usually diagnosed in or after the 4th decade. 
Global incidence is unknown, but the reported 
incidence from Sweden is 2 per million. 
However, it is estimated that 1 in 1000 of 
patients with diastolic hypertension have 
pheochromocytoma. Although uncommon, 
this disorder is important to diagnose because 
it may prove fatal in pregnant women during 
delivery and in patients undergoing surgery. 
Clinical manifestations vary but usually 
include persistent or paroxysmal 
hypertension, headache, sweating, 
tachycardia, tremor, nausea or vomiting, 
constipation, fatigue, abdominal or chest pain, 
weight loss and visual disturbances. In few 
patients the tumor is found incidentally on CT 
or MRI scan. 
Diagnosis and treatment: Assay of 
catecholamines and their metabolites 
(metanephrin and vanillymandelic acid) has 
markedly simplified the diagnosis of this 
disorder. Glucagon test to induce paroxysm or 
clonidine test to suppress noradrenaline or 
therapeutic trial with phenoxybenzamine are 
rarely needed to establish the diagnosis. Once 
the diagnosis is confirmed, the tumor must be 
localized to facilitate its surgical removal. CT 
and MRI are very efficient for that purpose. 
Radio-isotope scanning using iodine is useful 
for very small tumors and for extra-abdominal 
catecholamine-producing tumors (MIBG). 
Surgical treatment is curative, but pre-
operative treatment to control hypertension is 
mandatory. Drugs used for such therapy are 
adrenergic antagonists and include 
phentolamine, phenoxy benzamine, and 
prazosin. Propranolol (a beta blocker) is used 
to control marked tachycardia and arrhythmia, 
but it should not be given until alpha receptor 
blockade is established. 
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